| Literature DB >> 32677884 |
Dawood Al-Ajmi1, Shafeeq Rahman2, Sharmila Banu2.
Abstract
BACKGROUND: Shiga toxin-producing Escherichia coli (STEC) is a major source of food-borne illness around the world. E. coli O157 has been widely reported as the most common STEC serogroup and has emerged as an important enteric pathogen. Cattle, in particular have been identified as a major E. coli O157:H7 reservoir of human infections; however, the prevalence of this organism in camels, sheep, and goats is less understood. The aim of this study was to evaluate the occurrence and concentration of E. coli serotype O157 in the feces of healthy camels (n = 140), cattle (n = 137), sheep (n = 141) and goats (n = 150) slaughtered in United Arab Emirates (UAE) for meat consumption between September 2017 and August 2018. We used immunomagnetic separation coupled with a culture-plating method to detect E. coli O157. Non-sorbitol fermenting colonies were assessed via latex-agglutination testing, and positive cultures were analyzed by performing polymerase chain reactions to detect genes encoding attaching and effacing protein (eaeA), hemolysin A (hlyA, also known as ehxA) and Shiga toxin (stx1 and stx2), and E. coli O157:H7 specific genes (rfb O157, uidA, and fliC). All E. coli O157 isolates were analyzed for their susceptibility to 20 selected antimicrobials.Entities:
Keywords: Antimicrobial resistance; Escherichia coli O157; Food pathogen testing
Mesh:
Substances:
Year: 2020 PMID: 32677884 PMCID: PMC7364618 DOI: 10.1186/s12866-020-01899-0
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
E. coli O157-positive cases and the E. coli O157 concentrations in animal feces
| Species | Number of animals | Percentage (%) | ||
|---|---|---|---|---|
| Camel | 140 | 6 | 4.3 | 4 × 104 |
| Goat | 150 | 3 | 2.0 | 4 × 104 |
| Cattle | 137 | 2 | 1.46 | 2 × 103 |
| Sheep | 141 | 0 | 0.0 | 0 |
CFU colony-forming unit, used to estimate the number of viable bacteria cells in a sample
Distribution of virulent genes detected by PCR
| Sample number | Species | Genes | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Camel | + | + | – | – | + | + | – |
| 2 | Camel | + | + | + | – | + | + | – |
| 3 | Camel | + | – | – | – | + | + | – |
| 4 | Camel | + | + | – | – | – | + | – |
| 5 | Camel | + | + | + | – | + | + | – |
| 6 | Camel | + | – | + | – | + | + | – |
| 7 | Camel | + | – | + | – | + | + | – |
| 8 | Camel | + | + | + | – | + | + | – |
| 9 | Camel | + | + | + | – | + | + | – |
| 10 | Camel | + | + | + | – | + | + | – |
| 11 | Camel | + | – | + | – | + | + | – |
| 12 | Camel | + | – | + | – | + | + | – |
| 13 | Cattle | + | – | – | – | + | + | – |
| 14 | Cattle | + | + | + | – | + | + | – |
| 15 | Goat | + | – | – | – | – | + | – |
| 16 | Goat | + | – | + | – | + | + | – |
| 17 | Goat | + | – | + | – | + | + | – |
| 18 | Goat | + | – | – | – | – | + | – |
| 19 | Goat | + | – | – | – | – | + | – |
| 20 | Goat | + | – | + | – | + | + | – |
| 21 | Goat | + | – | + | – | + | + | – |
| 22 | Goat | + | – | + | – | + | + | – |
| 23 | Goat | + | – | + | – | + | + | – |
| 24 | Goat | + | – | – | – | – | + | – |
Antimicrobials used, their symbols, and corresponding zones of inhibition for gram-negative enteric bacteria
| Antimicrobial used | Symbol | Diameter of zone of inhibition (mm) | ||
|---|---|---|---|---|
| Resistant | Intermediate | Susceptible | ||
| Amoxicillin (25 μg) | AML | ≤13 | 14–16 | ≥17 |
| Ampicillin (10 μg) | AMP | ≤13 | 14–17 | ≥18 |
| Bacitracin (10 μg) | B | ≤14 | 15–16 | ≥17 |
| Cefotaxime (30 μg) | CTX | ≤14 | 15–22 | ≥23 |
| Cefoxitin (30 μg) | FOX | ≤14 | 15–17 | ≥18 |
| Ceftazidime (10 μg) | CAZ | ≤12 | 13–17 | ≥18 |
| Cefuroxime sodium (5 μg) | CXM | ≤14 | 15–22 | ≥23 |
| Chloramphenicol (30 μg) | CHL | ≤14 | 15–20 | ≥21 |
| Ciprofloxacin (30 μg) | CIP | ≤15 | 16–20 | ≥21 |
| Cloxacillin (5 μg) | CLOXA | ≤13 | 14–16 | ≥17 |
| Doxycycline (30 μg) | DO | ≤13 | 14–16 | ≥17 |
| Gentamycin (10 μg) | GEN | ≤12 | 13–15 | ≥16 |
| Kanamycin (30 μg) | K | ≤13 | 14–17 | ≥18 |
| Nalidixic acid (30 μg) | NAL | ≤13 | 14–18 | ≥19 |
| Nitrofurantoin (300 μg) | F | ≤13 | 14–17 | ≥18 |
| Norfloxacin (10 μg) | NOR | ≤12 | 13–16 | ≥17 |
| Polymyxin B (300 units) | PMB | ≤8 | 9–11 | ≥12 |
| Streptomycin (10 μg) | STR | ≤11 | 12–14 | ≥15 |
| Tetracycline (30 μg) | TET | ≤12 | 15–18 | ≥19 |
| Vancomycin (30 μg) | VAN | ≤14 | 15–16 | ≥17 |
Primers used to confirm the presence of E. coli O157:H7 and virulence genes
| Target gene | Primer name | Primer sequence (5′–3′) | Amplification size (bp) |
|---|---|---|---|
| O157AF | AAGATTGCGCTGAAGCCTTTG | 497 | |
| O157AR | CATTGGCATCGTGTGGACAG | ||
| FLICH7 F | GCGCTGTCGAGTTCTATCGAGC | 625 | |
| FLICH7 R | CAACGGTGACTTTATCGCCATTCC | ||
| PT-2 | GCGAAAACTGTGGAATTGGG | 252 | |
| PT-3 | TGATGCTCCATAACTTCCTG | ||
| hlyA F | GCATCATCAAGCGTACGTTCC | 534 | |
| hlyA R | AATGAGCCAAGCTGGTTAAGCT | ||
| Stx2F | GGCACTGTCTGAAACTGCTCC | 255 | |
| Stx2R | TCGCCAGTTATCTGACATTCTG | ||
| Stx1F | ATAAATCGCCATTCGTTGACTAC | 180 | |
| Stx1R | AGAACGCCCACTGAGATCATC |